Verastem, Inc.
NASDAQ:VSTMBiotechnology
-$0.00 today
- Market cap
- $865.72M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
Volume 3.97M
Average 2.58M
VSTM Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Verastem, Inc.NASDAQ: VSTM
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $28.69M fell 57.4% year over year, behind the +85.0% change in trailing-twelve-month financing cash flow. Sequentially, it fell 70.9% from the prior quarter. Over 3 fiscal years it compounded at +72.0% a year.
Context
- Financing cash flow amounted to 851.7% of revenue in FY2025, up 303.9 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -57.4% toward the trailing-twelve-month pace of +85.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 263.31M USD
- Year-over-year change
- +380.6%
- 4-year CAGR
- +148.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 263.31M | +380.6% |
| FY2024 | 2024-12-31 | 54.78M | -59.2% |
| FY2023 | 2023-12-31 | 134.19M | +159.1% |
| FY2022 | 2022-12-31 | 51.78M | +652.1% |
| FY2021 | 2021-12-31 | 6.89M | — |
Financing Cash Flow vs competitors
How VSTM compares with its peers on the latest reported figures
- VSTM's LTM Mar 2026 financing cash flow of $224.57M is the 3rd largest of the 11 companies compared; the peer median is $117.85M.
- Its year-over-year change of +85.0% is the 6th highest of 10, against a peer median of +1074.3%.
- Financing cash flow amounts to 452.9% of revenue for VSTM, versus a peer median of 271.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $402.65M | +1936.0% | — | — |
| LTM Mar 2026 | $306.39M | +17210.3% | +114.1% | — | |
| LTM Mar 2026 | $224.57M | +85.0% | +72.0% | 452.9% | |
| LTM Mar 2026 | $212.95M | +1074.3% | +2184.5% | — | |
| LTM Jun 2026 | $179.14M | -6.5% | +434.4% | 105.4% | |
| LTM Mar 2026 | $126.91M | +1085.3% | +379.4% | 364.0% | |
| LTM Jun 2024 | $108.79M | — | -17.4% | 1676.2% | |
| LTM Mar 2026 | $50.66M | -51.5% | -16.6% | 179.5% | |
| LTM Mar 2026 | $24.66M | +9371.4% | +212.3% | 147.5% | |
| LTM Mar 2026 | $2.68M | -95.0% | +225.3% | 511.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $439K | -100.4% | — | — |
| Peer median (excluding VSTM) | $117.85M | +1074.3% | +218.8% | 271.8% | |
Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.2M) | (73.81M) | (87.37M) | (130.64M) | (209.47M) |
| Depreciation & Amortization | 72K | (36K) | 62K | 26K | 728K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.71M | 6.05M | 5.86M | 7.34M | 9.4M |
| Change in Working Capital | 584K | 3.9M | (957K) | 3.72M | 26M |
| Accounts Receivables | (277K) | 485K | 31K | (200K) | (8.81M) |
| Inventory | 0 | 0 | 0 | 0 | (1.83M) |
| Accounts Payables | 623K | 2.6M | 2.28M | (3.16M) | 8.42M |
| Other Working Capital | 238K | 816K | (3.27M) | 7.08M | 28.23M |
| Other Non-Cash Items | 9.33M | 228K | (4.06M) | 14.78M | 35.83M |
| Operating Cash Flow | (53.5M) | (63.67M) | (86.46M) | (104.77M) | (137.51M) |
| Capital Expenditures | (196K) | 0 | 0 | (28K) | 0 |
| Acquisitions (Net) | 9.33M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (86.44M) | (17.82M) | (96.45M) | 0 | 0 |
| Sales of Investments | 86.73M | 84M | 52M | 60M | 29K |
| Other Investing Activities | (9.33M) | 0 | 0 | 5K | (29K) |
| Investing Cash Flow | 87K | 66.19M | (44.45M) | 59.97M | (9.62M) |
| Debt Repayment | 0 | 24.15M | 14.62M | (150K) | 32.42M |
| Common Stock Issued | 6.72M | 27.35M | 91.42M | 14.22M | 230.88M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 162K | 282K | 57K | 40.71M | 0 |
| Financing Cash Flow | 6.89M | 51.78M | 134.19M | 54.78M | 263.31M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (46.53M) | 54.3M | 3.29M | 9.98M | 116.17M |
| Free Cash Flow | (53.7M) | (63.67M) | (86.46M) | (104.8M) | (137.51M) |
Verastem, Inc.
NASDAQ:VSTM
Intrinsic Alpha fair value
Locked
Current Price
$6.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.